PUDONG, China - eTradeWire -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and above.

First Methylphenidate Combination Drug Poised to Benefit Patients in China

Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug.

More on eTradeWire News

• Ozge Fettahlioglu Links Neuroarchitecture, Biophilic Design and Property Value
• XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
• The National Coalition for Men to Blanket Chicago Area with Men's Billboard Campaign on Memorial Day
• New HVAC Company, Charm Air, Launches Across the Treasure Coast
• Laughter and Collaboration in Moonlight and Magnolias

Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control

- Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms.

- Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms.

- Stable Release Profile: Designed to support the full span of a patient's day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations.

Abuse-Deterrent Design

Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy.

Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial

More on eTradeWire News

• BetterVideo.io Launches With a Promise Most AI Companies Won't Make: Videos Will Never Train Our AI
• CourMed | The Historical Evolution of Legacy Wealth
• Blue Planet – Red Tide Debuts Amid Super El Niño and UAP Disclosure Headlines
• Historic Oaks, Urban Lights & Picture-Perfect Rides: GeorgiaMovieCars.com Arrives
• Elev8 Coaching Launches Certified Strong Interest Inventory® Services for Tech Professionals

- In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints.

- The study reported no drug related serious adverse events, affirming Azstarys's favorable safety and tolerability profile, critical for long-term use in pediatric settings.

Transforming ADHD Treatment Paradigm in China

As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians.

Azstarys® is a registered trademark of Corium in the United States.

For more information about the company, please visit our website: http://www.arkbiosciences.com

Investor Inquiries：IR@arkbiosciences.com